Daniel Laorden
Overview
Explore the profile of Daniel Laorden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laorden D, Dominguez-Ortega J, Romero D, Villamanan E, Mariscal-Aguilar P, Granda P, et al.
J Clin Med
. 2025 Jan;
14(2).
PMID: 39860330
Uncontrolled, severe asthma remains a significant clinical challenge, affecting a small proportion of asthma patients worldwide. Despite advancements in treatment options, a subset of patients continues to experience frequent exacerbations,...
2.
Villamanan E, Laorden D, Granda P, Sobrino C, De Andres S, Carpio C, et al.
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685611
Advances in knowledge about clinical features, physiology, and underlying immunology are leading to targeted therapies and a new era of therapies. Biological treatments for severe asthma have changed the way...
3.
Correa-Borit J, Laorden D, Arnalich Montiel V, Quirce S, Dominguez-Ortega J
J Asthma
. 2024 Dec;
:1-4.
PMID: 39661869
Response to biologics in severe uncontrolled asthma (SUA) can be classified as super-responders, good responders, non-responders, and those achieving clinical remission. The aim of this study is to evaluate the...
4.
Navarro-Cascales T, Colque-Bayona M, Fernandez-Concha I, Laorden D, Quirce S, Dominguez-Ortega J
J Asthma
. 2024 Sep;
62(2):319-327.
PMID: 39235972
Objective: This study aimed to compare the clinical characteristics and treatment outcomes of allergic patients (AP) and non-allergic patients (NAP) with severe eosinophilic asthma (SEA) treated with anti-IL5/IL5R biologic agents...
5.
Granda P, Villamanan E, Laorden D, Carpio C, Collada V, Dominguez-Ortega J, et al.
J Clin Med
. 2024 Aug;
13(15).
PMID: 39124568
: The prevalence of cardiovascular events (CVEs) in patients with asthma varies amongst studies, with little evidence as to their prevalence in patients treated with monoclonal antibodies (mAbs). In this...
6.
Granda P, Villamanan E, Carpio C, Laorden D, Quirce S, Alvarez-Sala R
J Asthma
. 2024 Jan;
61(8):857-866.
PMID: 38266131
Objective: The aim of this retrospective multicentre study is to describe the clinical characteristics of patients diagnosed with severe eosinophilic asthma receiving anti-IL-5/anti-IL-5Rα therapies and to compare their effectiveness. Methods:...
7.
Carpio C, Qasem A, Buno A, Borobia A, Arnalich F, Rey V, et al.
J Clin Med
. 2023 Oct;
12(19).
PMID: 37834944
To evaluate KL-6 levels in medium-term post-COVID and to compare them in three groups categorised by the severity of COVID-19, we conducted a real-world, retrospective, cohort study. Data from the...
8.
Dominguez-Ortega J, Laorden D, Vilchez-Sanchez F, Banas-Conejero D, Quirce S
J Asthma
. 2023 Jul;
61(1):39-47.
PMID: 37503953
Objective: To define the cost-effectiveness and health resource use of mepolizumab in a cohort of patients with severe eosinophilic asthma in real-life conditions in Spain. Methods: This was an observational,...
9.
Lorente-Gonzalez M, Garcia-Fadul C, Gijon-Herreros N, Rafael Teran-Tinedo J, Zevallos-Villegas A, Laorden D, et al.
Open Respir Arch
. 2023 Jul;
4(3):100173.
PMID: 37496591
No abstract available.
10.
Lorente-Gonzalez M, Rafael Teran-Tinedo J, Zevallos-Villegas A, Laorden D, Mariscal-Aguilar P, Suarez-Ortiz M, et al.
J Intensive Care Med
. 2023 Jun;
38(11):1023-1041.
PMID: 37306158
Introduction: The occurrence of pneumomediastinum (PM) and/or pneumothorax (PTX) in patients with severe pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was evaluated. Methods: This was a prospective...